The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Oxis Turbohaler 6, inhalation powder

6
Mcg/Acutuation Powder for Inhalation


AstraZeneca ABPA1019/015/001

Main Information

Trade NameOxis Turbohaler 6, inhalation powder
Active SubstancesFormoterol fumatrate dihydrate
Strength6
Mcg/Acutuation
Dosage FormPowder for Inhalation
Licence HolderAstraZeneca AB
Licence NumberPA1019/015/001

Group Information

ATC CodeR03AC Selective beta-2-adrenoreceptor agonists
R03AC13 formoterol

Status

Authorised/WithdrawnAuthorised
Licence Issued10/03/2002
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back